HC Wainwright Issues Optimistic Forecast for ACRS Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research report issued on Wednesday, October 28th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.61) per share for the year, up from their prior forecast of ($0.62). HC Wainwright currently has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.55) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $1.38 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.

ACRS has been the topic of a number of other reports. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Wedbush cut their price objective on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Wednesday. Canaccord Genuity Group initiated coverage on shares of Aclaris Therapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $11.00.

Aclaris Therapeutics Trading Up 0.8%

Aclaris Therapeutics stock opened at $3.99 on Friday. The stock has a fifty day moving average price of $4.93 and a 200 day moving average price of $4.51. Aclaris Therapeutics has a 52 week low of $2.10 and a 52 week high of $6.60. The firm has a market capitalization of $557.90 million, a P/E ratio of -6.88 and a beta of 0.87.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at about $53,096,000. Kalehua Capital Management LLC purchased a new stake in shares of Aclaris Therapeutics during the 1st quarter worth about $6,871,000. Palo Alto Investors LP purchased a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth about $8,535,045. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $6,400,000. Finally, Deutsche Bank AG acquired a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $5,507,000. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.